Employees protest against shutting down of GSK facility in Bangladesh
pharmafile | July 24, 2018 | News story | Manufacturing and Production | Bangladesh, GSK, manufacturing, protest, union
Employees of the British multinational GlaxoSmithKline (GSK) have led a protest against the shutting down of manufacturing facilities in Bangladesh.
The employees, who have organised under the banner of GlaxoSmithKline Employees’ Union, alleged that a self-seeking group has been conspiring to shut down production in the country, according to United News of Bangladesh.
The General Secretary of the Union, Mr Azam, alleged in a press conference at the Jatiya Press Club, that following the recent meeting of the company’s directors, the process of shutting down production in Bangladesh had begun, as the levels of production and marketing undertaken in the densely populated South Asian nation, had started to be reduced.
Azam stated that: “Although the employees are receiving salaries and other benefits, the company had decreased its production after Eid-ul-Fitr and now completely stop its production from July 22. We are suspecting that the authority will come up with an official declaration to shut down the company on July 26.” He added that no raw materials had been bought after the month of June.
The General Secretary further noted that the company had earned revenue of 10 million Bangladeshi Taka (equivalent to approximately ÂŁ90,000) between 2013 and 2017. The Bangladeshi government had earned a sizeable portion of this due to the fact that they are an 18% stakeholder in the company.
However Alhajj Sarker, the advisor of the employee’s union urged the government to intervene on the issue as the shutting down of manufacturing could leave hundreds of workers jobless.
Louis Goss
Related Content
GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment
GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand …
GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients
GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory …
Eli Lilly increases manufacturing investment to $9bn at new Indiana site
Eli Lilly has announced that it has more than doubled its investment at its Lebanon, …